First Results and Actual Prospects
Within the nine months of this year improved financial performance of Russian pharmaceutical companies has been observed.
To a large extent it is caused by increased price for drugs. But Russian manufacturers of generics are not hasty in increasing prices for their products, which increases their competitiveness. In that respect analysts report increased sales of drugs manufactured in Russia, with prices increasing slower even taking into account purchase of imported raw materials.
PAO Protek profit has increased by one third to 4.9 bln rubles, which is 1.2 bln rubles above the same period last year. H1 sales of PAO Pharmstandard increased almost twice from 1.66 bln rubles to over 3 bln rubles.
Analysts suggest development of import substitution. The forecast is supported by the activity of increasing input into new lines by manufacturers.